微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 55.33% | -12.73% | -0.54% | 65/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 55.63% | -14.54% | -2.09% | 64/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 56.82% | -12.34% | -11.76% | 58/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 64.39% | -7.13% | 1.56% | 43/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 63.4% | -8.48% | -2.61% | 42/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 65.1% | -6.97% | 0.43% | 42/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 64.82% | -8.43% | -6.51% | 37/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 69.33% | -5.67% | 0.08% | 34/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 69.27% | -5.54% | -1.01% | 36/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 69.98% | -2.3% | -1.14% | 36/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 70.78% | -3.48% | -3.7% | 36/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 73.5% | 2.84% | 0.22% | 34/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 73.34% | 3.94% | 2.39% | 36/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 71.63% | 0.04% | -2.32% | 38/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 73.33% | 1.41% | 2.61% | 35/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 71.47% | 4.96% | 1.29% | 40/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 70.56% | 1.08% | -1.46% | 35/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 71.6% | 0.17% | -0.98% | 35/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 72.31% | 1.1% | 6.2% | 27/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 68.09% | -5.12% | -2.45% | 43/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 69.8% | 0.52% | -2.35% | 34/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 71.48% | 2.33% | -0.06% | 29/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 71.52% | 9.02% | -0.34% | 26/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 71.76% | 18.04% | 3.35% | 37/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 69.44% | 15.23% | -0.59% | 28/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 69.85% | 21.33% | 6.47% | 30/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 65.61% | 14.96% | 7.91% | 29/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 60.8% | 24.47% | 0.89% | 50/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 60.26% | 35.07% | 4.67% | 40/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 57.57% | 44.11% | 0.89% | 45/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 57.07% | 44.97% | 16.84% | 44/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 48.84% | 16.8% | 9.48% | 66/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 44.62% | 12.71% | 11.68% | 53/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 39.95% | 5.14% | 1.49% | 62/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 39.37% | 8.81% | -5.87% | 49/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 41.82% | 12.8% | 5.65% | 65/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 39.58% | 15.44% | 4.18% | 45/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 38% | 4.7% | 5.02% | 55/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 36.18% | 6.15% | -2.41% | 48/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 37.07% | 16.03% | 8.12% | 63/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 34.29% | 8.16% | -5.52% | 51/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 36.29% | 20.6% | 6.49% | 52/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 34.08% | 8.86% | 6.67% | 47/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |